Phase 3 clinical trial begins in mild to moderate Alzheimer's Disease

Oct 30 - 2012 06:03 PM
Phase 3 clinical trial begins in mild to moderate Alzheimer's Disease with a second-generation Tau Aggregation Inhibitor (TAI) aimed at halting the progression of Alzheimer's.
Read more

Phase 3 clinical trial begins in FTD, an early form of dementia

Sep 28 - 2012 11:00 PM
Phase 3 clinical trial begins in early form of dementia
Read more

US patent granted: Patent for TauRx’s next generation Tau Aggregation Inhibitor

Sep 30 - 2011 06:57 AM
US patent granted: Patent for TauRx’s next generation Tau Aggregation Inhibitor compound granted extensively
Read more

TauRx’s recent Rights Issue over-subscribed

Jul 05 - 2010 07:11 AM
TauRx’s recent Rights Issue exercise which closed on 2 July 2010 was over-subscribed by 3.52%. TauRx would like to thank our shareholders for their encouragement and strong support. Shareholders will be receiving the new share certificates via registered mail shortly.
Read more

Announcement: TauRx Rights Issue closure extends to 2 July 2010

Jul 02 - 2010 05:45 AM
TauRx has extended a Rights Issue which was initially scheduled to close on 29 June 2010
Read more